Gland Pharma Ltd
GLANDGland Pharma Ltd
GLAND
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 42.76 | 4.15 | 1.00% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 11 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,384.63 | 1,512.74 | 1,668.73 | 2,129.76 | 2,772.41 | 3,597.66 | 4,624.65 | 3,865.06 | 5,834.96 | 5,834.97 | ||||||||||
Raw Materials | 530.72 | 463.36 | 727.42 | 971.18 | 1,108.93 | 1,765.36 | 2,072.53 | 1,732.34 | 4,331.65 | 4,331.66 | ||||||||||
| Power & Fuel Cost | 46.96 | 49.24 | 60.35 | 74.03 | 78.50 | 74.59 | 95.05 | 124.84 | ||||||||||||
| Employee Cost | 131.30 | 153.42 | 179.08 | 222.95 | 277.66 | 311.36 | 338.57 | 403.26 | ||||||||||||
| Selling & Administrative Expenses | 53.92 | 74.75 | 108.29 | 82.52 | 98.54 | 128.48 | 177.92 | 187.93 | ||||||||||||
| Operating & Other expenses | 82.74 | 113.42 | 9.69 | 7.22 | 114.15 | -119.14 | 206.49 | 207.92 | ||||||||||||
EBITDA | 538.99 | 658.55 | 583.90 | 771.86 | 1,094.63 | 1,437.01 | 1,734.09 | 1,208.77 | 1,503.31 | 1,503.31 | ||||||||||
| Depreciation/Amortization | 63.46 | 74.15 | 78.21 | 81.96 | 94.59 | 98.78 | 110.30 | 146.74 | 344.57 | 344.57 | ||||||||||
| PBIT | 475.53 | 584.40 | 505.69 | 689.90 | 1,000.04 | 1,338.23 | 1,623.79 | 1,062.03 | 1,158.74 | 1,158.74 | ||||||||||
| Interest & Other Items | 16.42 | 6.39 | 4.13 | 3.56 | 7.18 | 3.41 | 5.24 | 7.45 | 26.20 | 26.21 | ||||||||||
| PBT | 459.11 | 578.01 | 501.56 | 686.34 | 992.86 | 1,334.82 | 1,618.55 | 1,054.58 | 1,132.54 | 1,132.53 | ||||||||||
| Taxes & Other Items | 145.51 | 164.29 | 180.44 | 234.45 | 220.01 | 337.85 | 406.89 | 273.54 | 360.08 | 360.08 | ||||||||||
| Net Income | 313.60 | 413.72 | 321.12 | 451.89 | 772.85 | 996.97 | 1,211.66 | 781.04 | 772.46 | 772.45 | ||||||||||
| EPS | 20.12 | 26.70 | 20.72 | 29.16 | 49.88 | 62.60 | 73.91 | 47.48 | 46.90 | 46.90 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gland Pharma Ltd | 42.76 | 4.15 | 1.00% |
| Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
| Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
| Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare GLAND with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 6.03%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 3.29%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 7.52%
Top 5 Mutual Funds holding Gland Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.9602% | Percentage of the fund’s portfolio invested in the stock 1.39% | Change in the portfolio weight of the stock over the last 3 months 0.50% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/76 (+2) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.8505% | Percentage of the fund’s portfolio invested in the stock 1.62% | Change in the portfolio weight of the stock over the last 3 months -0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/108 (0) |
Nippon India Growth Fund - Growth Option - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.4482% | Percentage of the fund’s portfolio invested in the stock 1.55% | Change in the portfolio weight of the stock over the last 3 months 0.75% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 62/101 (+8) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹20.00
Ex DateEx Date
Aug 16, 2024
Past Dividends
No past dividends are available
U.S. FDA issues two observations for Gland Pharma facility
Gland Pharma’s Hyderabad Facility Gets Two US FDA Observations
USFDA conducts surprise inspection of Gland Pharma’s Dundigal facility
Gland Pharma announced that the United States Food and Drug Administration (US FDA) has conducted surprise inspection of the Company's Dundigal Facility at Hyderabad for Good Manufacturing Practices (GMP) between 22 July 2024 and 25 July 2024. The inspection was concluded with TWO (2) 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity. Powered by Capital Market - Live
Gland Pharma receives USFDA tentative approval for Latanoprostene Bunod Ophthalmic Solution
Gland Pharma has received tentative approval from the United States Food and Drug Administration (USFDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024%. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vyzulta' Ophthalmic Solution, 0.024%, registered by Bausch & Lomb Inc. (Bausch & Lomb). Based on the available updates, the Company believes that it is the first applicant to have filed its ANDA with Paragraph IV certification. Upon final approval, the Company may be eligible for 180 days of generic drug exclusivity. Latanoprostene Bunod Ophthalmic Solution, 0.024%, is indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. According to IQVIA, the product had US sales of approximately USD 153 million for the twelve months ended December 2023. Powered by Capital Market - Live
Gland Pharma gets USFDA nod for glaucoma drug
Gland Pharma, Zydus Lifesciences secure USFDA approvals for key medications
Technical Analysis: Gland Pharma, Tata Teleservices (Maharashtra) and Timken India
Gland Pharma will hold a meeting of the Board of Directors of the Company on 6 August 2024.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 22.33%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 0.94% to 1.59%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.32%, vs industry avg of 15.15%